SAN DIEGO--(BUSINESS WIRE)--Sep. 8, 2017--
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, announced today that Douglas Bryant,
president and chief executive officer, and Randy Steward, chief
financial officer, will participate in the CEO Series Conference Call,
hosted by Canaccord Genuity on Monday, September 11, 2017 at 11:00 a.m.
Eastern time (8:00 a.m. Pacific time).
During the presentation, the company will discuss business and financial
developments and trends, which may include discussion of the Company’s
pending acquisition of assets of the Triage® MeterPro cardiovascular and
toxicology business, and the Triage BNP business from Alere Inc. The
company's statements may contain or constitute material information that
has not been previously disclosed.
The conference call may be accessed by dialing (877) 930-5791 for
participants in the U.S./Canada or (253) 336-7286 for participants
outside the U.S./Canada using the required conference ID 83358293. A
live webcast and audio archive of the conference call will be available
via the Investor Relations section of the company’s Web site at http://ir.quidel.com
About Quidel Corporation
Quidel Corporation serves to enhance the health and well-being of people
around the globe through the development of diagnostic solutions that
can lead to improved patient outcomes and provide economic benefits to
the healthcare system. Marketed under the Sofia®, QuickVue®, D3® Direct
Detection, Thyretain® and InflammaDry® leading brand names, as well as
under the new Solana®, AmpliVue® and Lyra® molecular diagnostic brands,
Quidel’s products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza, respiratory
syncytial virus, Strep A, herpes, pregnancy, thyroid disease and fecal
occult blood. Quidel’s research and development engine is also
developing a continuum of diagnostic solutions from advanced
lateral-flow and direct fluorescent antibody to molecular diagnostic
tests to further improve the quality of healthcare in physicians’
offices and hospital and reference laboratories. For more information
about Quidel’s comprehensive product portfolio, visit quidel.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170908005445/en/
Source: Quidel
For Quidel Corporation
Randy Steward
Chief Financial Officer
(858)
552-7931
or
Victoria Sivrais
Clermont Partners
(312)
690-6004
vsivrais@clermontpartners.com